EDIT News and Press, Editas Medicine Inc. From 08/25/22

Summary Editas' engraftment trial experiment made positive headway in Q2 2022 after a patient was successfully treated for sickle cell disease. Editas Medicine is expected to announce the top-line clinical results for the RUBY trial by the end of 2022. Editas Medicine has a hi...

Results from phase 1/2 BRILLIANCE study using EDIT-101 (Cas9 nuclease) for the treatment of patients with Leber Congenital Amaurosis 10 expected 2nd half of 2022. Results from the phase 1/2 RUBY study using EDIT-301 (AsCas12a nuclease) for the treatment of patients with sickle cell di...

Editas Medicine, Inc. (EDIT) Q2 2022 Earnings Conference Call August 3, 2022 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Jim Mullen - Executive Chairman Gilmore O’Neill - Chief Executive Officer Mark Shearman - Chief Scientific Of...

Shares of Editas Medicine (NASDAQ: EDIT) were rocketing more than 13% higher in late-afternoon trading on Wednesday, and it was little wonder. The company scored twin beats in its latest set of quarterly results, with one line item in particular being a standout. Prior to market...

Editas Medicine ( NASDAQ: EDIT ) is up 13% in Wednesday morning trading after beating analyst estimates on both Q2 2022 EPS and revenue . The genome editing company saw its net loss narrow 3% year over year to ~$53.5M (-$0.78 per share basic and diluted vs. -$0.81)...

Editas Medicine press release ( NASDAQ: EDIT ): Q2 GAAP EPS of -$0.78 beats by $0.06 . Revenue of $6.36M (+1573.7% Y/Y) beats by $2.07M . For further details see: Editas Medicine GAAP EPS of -$0.78 beats by $0.06, revenue of $6.36M beats by $2.07M

Appointed Baisong Mei, M.D., Ph.D., Chief Medical Officer, strengthening senior leadership team Achieved successful engraftment of first patient treated with EDIT-301 for sickle cell disease; first clinical use of Editas-engineered AsCas12a enzyme FDA removed partial clini...

Editas Medicine ( NASDAQ: EDIT ) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, before market open. The consensus EPS Estimate is -$0.80 (+1.2% Y/Y) and the consensus Revenue Estimate is $4.29M (+1028.9% Y/Y). Over the last 1 year, EDIT has be...

Successful engraftment of first patient dosed with EDIT-301 for sickle cell disease FDA removed partial clinical hold for the RUBY trial in EDIT-301 First clinical use of Editas-engineered AsCas12a enzyme Initial clinical data from the RUBY trial expected by year...

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 3, 2022, at 8:00 a.m. ET to provide financial results and corp...